Research

The first 12 months of COVID-19: a timeline of immunological insights

The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome

Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19

Immunogenicity of the Ad26.COV2.S vaccine for COVID-19

Association of clinical, biological, and brain magnetic resonance imaging findings with electroencephalographic findings for patients with COVID-19

Four-month clinical status of a cohort of patients after hospitalization for COVID-19

EEG Abnormalities are Common in COVID-19 and are Associated with Outcomes

Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19 a systematic review and meta-analysis

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

SARS-CoV-2 within-host diversity and transmission

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England